HomeCompareSSMXY vs CHD

SSMXY vs CHD: Dividend Comparison 2026

SSMXY yields 1.20% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHD wins by $1.3K in total portfolio value
10 years
SSMXY
SSMXY
● Live price
1.20%
Share price
$8.69
Annual div
$0.10
5Y div CAGR
20.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$975.85
Full SSMXY calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — SSMXY vs CHD

📍 CHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSMXYCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSMXY + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSMXY pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSMXY
Annual income on $10K today (after 15% tax)
$102.07/yr
After 10yr DRIP, annual income (after tax)
$829.47/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, CHD beats the other by $277.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSMXY + CHD for your $10,000?

SSMXY: 50%CHD: 50%
100% CHD50/50100% SSMXY
Portfolio after 10yr
$25.8K
Annual income
$1,139.25/yr
Blended yield
4.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

SSMXY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
5.0
Piotroski
6/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSMXY buys
0
CHD buys
11
PoliticianChamberTickerTypeAmountDate
Richard W. Allen🏢 House$CHD▼ Sell$15,001 - $50,0002025-10-10
Ro Khanna🏢 House$CHD▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-08-04
Ro Khanna🏢 House$CHD▲ Buy$1,000 - $15,0002025-08-04
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-06-17
Jonathan Jackson🏢 House$CHD▼ Sell$15,001 - $50,0002025-05-14
Jonathan Jackson🏢 House$CHD▼ Sell$1,001 - $15,0002025-05-05
Jonathan Jackson🏢 House$CHD▲ Buy$1,001 - $15,0002025-04-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSMXYCHD
Forward yield1.20%1.28%
Annual dividend / share$0.10$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR20.8%23.1%
Portfolio after 10y$25.1K$26.4K
Annual income after 10y$975.85$1,302.64
Total dividends collected$4.4K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: SSMXY vs CHD ($10,000, DRIP)

YearSSMXY PortfolioSSMXY Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$10,845$145.06$10,857$157.30$12.00CHD
2$11,782$177.60$11,814$196.49$32.00CHD
3$12,824$217.83$12,887$245.97$63.00CHD
4$13,990$267.69$14,097$308.68$107.00CHD
5$15,299$329.67$15,473$388.49$174.00CHD
6$16,777$407.02$17,046$490.55$269.00CHD
7$18,455$503.90$18,861$621.76$406.00CHD
8$20,373$625.80$20,973$791.47$600.00CHD
9$22,579$779.92$23,454$1,012.51$875.00CHD
10$25,135$975.85$26,398$1,302.64$1.3KCHD

SSMXY vs CHD: Complete Analysis 2026

SSMXYStock

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Full SSMXY Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this SSMXY vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSMXY vs SCHDSSMXY vs JEPISSMXY vs OSSMXY vs KOSSMXY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.